These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

341 related articles for article (PubMed ID: 28779222)

  • 1. [First line therapy for locally advanced or metastatic urothelial cancer : A randomized double blind phase III multicenter study on adjuvant nivolumab therapy versus placebo in patients with invasive high-risk urothelial cancer (CheckMate 274)-AB 58/17 of the AUO].
    Rexer H; Ohlmann CH; Gschwend J;
    Urologe A; 2017 Oct; 56(10):1331-1332. PubMed ID: 28779222
    [No Abstract]   [Full Text] [Related]  

  • 2. Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma.
    Bajorin DF; Witjes JA; Gschwend JE; Schenker M; Valderrama BP; Tomita Y; Bamias A; Lebret T; Shariat SF; Park SH; Ye D; Agerbaek M; Enting D; McDermott R; Gajate P; Peer A; Milowsky MI; Nosov A; Neif Antonio J; Tupikowski K; Toms L; Fischer BS; Qureshi A; Collette S; Unsal-Kacmaz K; Broughton E; Zardavas D; Koon HB; Galsky MD
    N Engl J Med; 2021 Jun; 384(22):2102-2114. PubMed ID: 34077643
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Second-line treatment of metastatic urothelial carcinoma : Update immuno-oncology].
    Zschäbitz S; Niegisch G
    Urologe A; 2020 Jul; 59(7):804-809. PubMed ID: 32472222
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bempegaldesleukin/Nivolumab and Challenges in First-line Treatment of Metastatic Urothelial Carcinoma.
    Miron B; Geynisman DM
    Eur Urol; 2022 Oct; 82(4):374-376. PubMed ID: 35752503
    [No Abstract]   [Full Text] [Related]  

  • 5. Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial.
    Sharma P; Retz M; Siefker-Radtke A; Baron A; Necchi A; Bedke J; Plimack ER; Vaena D; Grimm MO; Bracarda S; Arranz JÁ; Pal S; Ohyama C; Saci A; Qu X; Lambert A; Krishnan S; Azrilevich A; Galsky MD
    Lancet Oncol; 2017 Mar; 18(3):312-322. PubMed ID: 28131785
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Phase 2 Study of Sitravatinib in Combination with Nivolumab in Patients with Advanced or Metastatic Urothelial Carcinoma.
    Msaouel P; Sweis RF; Bupathi M; Heath E; Goodman OB; Hoimes CJ; Milowsky MI; Davis N; Kalebasty AR; Picus J; Shaffer D; Mao S; Adra N; Yorio J; Gandhi S; Grivas P; Siefker-Radtke A; Yang R; Latven L; Olson P; Chin CD; Der-Torossian H; Mortazavi A; Iyer G
    Eur Urol Oncol; 2024 Aug; 7(4):933-943. PubMed ID: 38105142
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ESMO Clinical Practice Guideline interim update on first-line therapy in advanced urothelial carcinoma.
    Powles T; Bellmunt J; Comperat E; De Santis M; Huddart R; Loriot Y; Necchi A; Valderrama BP; Ravaud A; Shariat SF; Szabados B; van der Heijden MS; Gillessen S;
    Ann Oncol; 2024 Jun; 35(6):485-490. PubMed ID: 38490358
    [No Abstract]   [Full Text] [Related]  

  • 8. Re: Erdafitinib or Chemotherapy in Advanced or Metastatic Urothelial Carcinoma.
    Tilgener C; Bedke J
    Eur Urol; 2024 Jun; 85(6):591-592. PubMed ID: 38538421
    [No Abstract]   [Full Text] [Related]  

  • 9. Chemotherapy of metastatic bladder cancer.
    Yagoda A
    Cancer; 1980 Apr; 45(7 Suppl):1879-88. PubMed ID: 7189443
    [No Abstract]   [Full Text] [Related]  

  • 10. [First-line therapy for locally advanced or metastatic urothelial carcinoma : A randomized, controlled phase III trial comparing pembrolizumab with or without platinum-based combination chemotherapy and chemotherapy only in patients with advanced or metastatic urothelial carcinoma (keynote 361-AB 54/16 of the AUO)].
    Rexer H; Ohlmann CH; Retz M
    Urologe A; 2017 May; 56(5):659-661. PubMed ID: 28349185
    [No Abstract]   [Full Text] [Related]  

  • 11. Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial.
    Petrylak DP; de Wit R; Chi KN; Drakaki A; Sternberg CN; Nishiyama H; Castellano D; Hussain S; Fléchon A; Bamias A; Yu EY; van der Heijden MS; Matsubara N; Alekseev B; Necchi A; Géczi L; Ou YC; Coskun HS; Su WP; Hegemann M; Percent IJ; Lee JL; Tucci M; Semenov A; Laestadius F; Peer A; Tortora G; Safina S; Del Muro XG; Rodriguez-Vida A; Cicin I; Harputluoglu H; Widau RC; Liepa AM; Walgren RA; Hamid O; Zimmermann AH; Bell-McGuinn KM; Powles T;
    Lancet; 2017 Nov; 390(10109):2266-2277. PubMed ID: 28916371
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial.
    Sharma P; Callahan MK; Bono P; Kim J; Spiliopoulou P; Calvo E; Pillai RN; Ott PA; de Braud F; Morse M; Le DT; Jaeger D; Chan E; Harbison C; Lin CS; Tschaika M; Azrilevich A; Rosenberg JE
    Lancet Oncol; 2016 Nov; 17(11):1590-1598. PubMed ID: 27733243
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gemcitabine with cisplatin and nivolumab: Redefining standard of care for first-line metastatic urothelial carcinoma?
    Mathew Thomas V; Grivas P; Agarwal N
    Med; 2024 Feb; 5(2):109-111. PubMed ID: 38340704
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel agents for muscle-invasive and advanced urothelial cancer.
    Sonpavde G; Ross R; Powles T; Sweeney CJ; Hahn N; Hutson TE; Galsky MD; Lerner SP; Sternberg CN
    BJU Int; 2008 Apr; 101(8):937-43. PubMed ID: 18005203
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical Validation of Chemotherapy Response Biomarker ERCC2 in Muscle-Invasive Urothelial Bladder Carcinoma.
    Liu D; Plimack ER; Hoffman-Censits J; Garraway LA; Bellmunt J; Van Allen E; Rosenberg JE
    JAMA Oncol; 2016 Aug; 2(8):1094-6. PubMed ID: 27310333
    [No Abstract]   [Full Text] [Related]  

  • 16. Front-line Platinum Continues To Have a Role in Advanced Bladder Cancer.
    Vogl UM; Testi I; De Santis M
    Eur Urol Focus; 2024 Mar; 10(2):217-218. PubMed ID: 38582643
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Adjuvant study of high-risk muscle invasive urothelial carcinoma : Open-label, multicenter, randomized phase III study with atezolizumab (anti-PD-L1 antibody) as adjuvant therapy compared with observation in patients with high-risk muscle invasive urothelial carcinoma after surgical resection (IMvigor010)- study AB 53/15 of the AUO].
    Rexer H; Retz M; Albers P
    Urologe A; 2016 Nov; 55(11):1491-1493. PubMed ID: 27714413
    [No Abstract]   [Full Text] [Related]  

  • 18. New treatments for patients with progressive metastatic urothelial carcinoma.
    Rosenberg JE
    Clin Adv Hematol Oncol; 2021 Mar; 19(3):180-183. PubMed ID: 33739967
    [No Abstract]   [Full Text] [Related]  

  • 19. Urothelial cancers: using biology to improve outcomes.
    Pezaro C; Liew MS; Davis ID
    Expert Rev Anticancer Ther; 2012 Jan; 12(1):87-98. PubMed ID: 22149435
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Financial toxicity from newly approved second-/third-line agents in metastatic urothelial carcinoma.
    Benjamin DJ; Lythgoe MP; Rezazadeh A
    BJU Int; 2023 Jun; 131(6):691-693. PubMed ID: 36877951
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 18.